S-217622 is the first oral, non-covalent, non-peptidic SARS-CoV-2 3CL (main protease) inhibitor clinical candidate, currently in Ph. II/III trials as a once-daily oral treatment for COVID-19. Unlike paxlovid , the molecule is a non-covalent inhibitor, which may lead to a better safety profile in large populations, though there is no reason to [...]